comprehensive -WSS

comprehensive

author：hotspot 2025-10-03 00:22:12 - browse：6

Golden brain and DNA spiral illustration. -- biotech coverage from STAT — Adobe

The dream of being able to pluck a cell therapy off of a freezer shelf and speedily give it to cancer patients is materializing in the cancer world. Now, a new biotech hopes to do the same for patients with neurological conditions.

Kenai Therapeutics closed a $82 million Series A round Thursday co-led by Cure Ventures, The Column Group, and sovereign wealth fund Alaska Permanent Fund Corp. The San Diego-based biotech has big plans for that money — it’s already identified its lead drug candidate for people with Parkinson’s disease, and plans to move into a clinical trial within the next year.

Kenai — pronounced key-nigh — is developing therapies that use induced pluripotent stem cells, or iPSCs. These highly versatile organisms are derived from skin or blood cells and can be transformed into any type of cell. In Parkinson’s, the idea is that these cells would replace damaged neurons.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Personalized medicine goes far beyond genetics

WSS

Flint parents haunted by uncertainty, fears of lead poisoning

Childhood cancer progress stalls for Black, Hispanic kids: Report

A controversial new treatment promises to make little people taller

The a glaring gap in research on serious mental illness and primary care

CDC recommends RSV monoclonal antibody for infants

Alnylam reports growth in sales of rare disease treatments

leisure time

comprehensive

entertainment

Psychedelics group wrestles with new pharma identity

Group behind ProMed defends move to subscription

Continuity nursing helped my family in our darkest PICU moments

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Continuity nursing helped my family in our darkest PICU moments

Medicare slashes safety net hospital payments by nearly $1 billion

Alkermes shareholders re

Poor hospice wound care hurts patients and families

State Dept. review finds Biden bears some blame for Afghanistan failures

Late stage cancers on the rise after pandemic delayed screenings

focus

Anthos stroke drug appears safer than common blood thinner

Medicare slashes safety net hospital payments by nearly $1 billion

Personalized medicine goes far beyond genetics

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Ransomware attacks on hospitals: Study outlines patient impact

'Null' research findings aren't empty of meaning. Let's publish them

leisure time

focus

leisure time

focus